Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (61-70 of 162) with videos related to

Pageof 17
Sort By:
The American Journal of Gastroenterology|February 20, 2013
Antibody response to infliximab and its impact on pharmacokinetics can be transientNiels Vande Casteele, Ann Gils, Sharat Singh, et al.
The Journal of Biological Chemistry|April 6, 2006
Generation of a stable activated thrombin activable fibrinolysis inhibitor variantErik Ceresa, Kirsten Van de Borne, Miet Peeters, et al.
Journal of Crohn'S & Colitis|September 22, 2018
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
European Journal of Gastroenterology & Hepatology|October 30, 2015
Thromboembolism as an important complication of inflammatory bowel diseaseLize Bollen, Niels Vande Casteele, Vera Ballet, et al.
Inflammatory Bowel Diseases|August 19, 2015
An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel DiseasesThomas Van Stappen, Thomas Billiet, Niels Vande Casteele, et al.
Therapeutic Drug Monitoring|January 12, 2019
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 12, 2019
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Clinical Nutrition (Edinburgh, Scotland)|September 4, 2016
Micronutrient intake, from diet and supplements, and association with status markers in pre- and post-RYGB patientsIna Gesquiere, Veerle Foulon, Patrick Augustijns, et al.
Thrombosis and Haemostasis|January 10, 2014
In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobodyMaarten L V Hendrickx, Monika Zatloukalova, Gholamreza Hassanzadeh-Ghassabeh, et al.
The European Journal of General Practice|February 24, 2026
Motivational factors for general practice training and career establishment: A cross-sectional study in Flanders, BelgiumLotta E Coenen, Madieke Maseman, Janique Lobbestael, et al.
Pageof 17

Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
The American Journal of Gastroenterology|February 20, 2013
Antibody response to infliximab and its impact on pharmacokinetics can be transientNiels Vande Casteele, Ann Gils, Sharat Singh, et al.
The Journal of Biological Chemistry|April 6, 2006
Generation of a stable activated thrombin activable fibrinolysis inhibitor variantErik Ceresa, Kirsten Van de Borne, Miet Peeters, et al.
Journal of Crohn'S & Colitis|September 22, 2018
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
European Journal of Gastroenterology & Hepatology|October 30, 2015
Thromboembolism as an important complication of inflammatory bowel diseaseLize Bollen, Niels Vande Casteele, Vera Ballet, et al.
Inflammatory Bowel Diseases|August 19, 2015
An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel DiseasesThomas Van Stappen, Thomas Billiet, Niels Vande Casteele, et al.
Therapeutic Drug Monitoring|January 12, 2019
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 12, 2019
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Clinical Nutrition (Edinburgh, Scotland)|September 4, 2016
Micronutrient intake, from diet and supplements, and association with status markers in pre- and post-RYGB patientsIna Gesquiere, Veerle Foulon, Patrick Augustijns, et al.
Thrombosis and Haemostasis|January 10, 2014
In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobodyMaarten L V Hendrickx, Monika Zatloukalova, Gholamreza Hassanzadeh-Ghassabeh, et al.
The European Journal of General Practice|February 24, 2026
Motivational factors for general practice training and career establishment: A cross-sectional study in Flanders, BelgiumLotta E Coenen, Madieke Maseman, Janique Lobbestael, et al.
Pageof 17